Seres Therapeutics (Germany) Top Insiders
1S9 Stock | EUR 0.83 0.05 5.68% |
Seres Therapeutics employs about 333 people. The company is managed by 25 executives with a total tenure of roughly 117 years, averaging almost 4.0 years of service per executive, having 13.32 employees per reported executive. Examination of Seres Therapeutics' management performance can provide insight into the company performance.
Eric Shaff CEO President, Chief Executive Officer, Director |
Eric MBA CEO CEO Pres |
Seres |
Seres Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4018) % which means that it has lost $0.4018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9017) %, meaning that it generated substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seres Therapeutics Workforce Comparison
Seres Therapeutics is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 100,334. Seres Therapeutics adds roughly 333 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Seres Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Seres Therapeutics Price Series Summation is a cross summation of Seres Therapeutics price series and its benchmark/peer.
Seres Therapeutics Notable Stakeholders
A Seres Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Seres Therapeutics often face trade-offs trying to please all of them. Seres Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Seres Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Eric Shaff | President, Chief Executive Officer, Director | Profile | |
Eric MBA | CEO Pres | Profile | |
Stephen Berenson | Independent Chairman of the Board | Profile | |
Thomas DesRosier | Chief Legal Officer, Executive Vice President and Secretary | Profile | |
David Ege | Executive Vice President, Chief Technology Officer | Profile | |
Marcus Chapman | Senior Vice President - Finance and Principal Financial and Accounting Officer | Profile | |
John Aunins | Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer | Profile | |
Matthew Henn | Executive Vice President Chief Scientific Officer | Profile | |
David MBA | CFO VP | Profile | |
Dennis Ausiello | Independent Director | Profile | |
Willard Dere | Independent Director | Profile | |
Richard Kender | Independent Director | Profile | |
Meryl Zausner | Independent Director | Profile | |
Kurt Graves | Independent Director | Profile | |
Gregory Behar | Independent Director | Profile | |
Paul Biondi | Independent Director | Profile | |
Jeff York | VP HR | Profile | |
SPHR SHRMSCP | Ex Officer | Profile | |
Carlo Tanzi | Head of Investor Relations and Corporate Communications | Profile | |
Kristin Ainsworth | Sr Communications | Profile | |
JD Esq | Exec Officer | Profile | |
Lisa MD | Ex Officer | Profile | |
Jayne Gansler | Chief People Officer, Executive Vice President | Profile | |
Lisa Moltke | Executive Vice President Chief Medical Officer | Profile | |
Terri Young | Executive Vice President Chief Commercial and Strategy Officer | Profile |
About Seres Therapeutics Management Performance
The success or failure of an entity such as Seres Therapeutics often depends on how effective the management is. Seres Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Seres management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Seres management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.
Seres Therapeutics Workforce Analysis
Traditionally, organizations such as Seres Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Seres Therapeutics within its industry.Seres Therapeutics Manpower Efficiency
Return on Seres Therapeutics Manpower
Revenue Per Employee | 435.2K | |
Revenue Per Executive | 5.8M | |
Net Loss Per Employee | 196.9K | |
Net Loss Per Executive | 2.6M |
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |